BKBelinda M. Kumpel

Belinda M. Kumpel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Belinda M. Kumpel has a total of 42 co-authors. Here are the top co-authors by number of shared publications:

  • A.M Wilkes

    International Blood Group Reference Laboratory, Bristol Institute of Transfusion Sciences, Southmead Road, Bristol BS10 5ND, UK

    1 shared publication
  • Ann P. MacDonald

    1 shared publication
  • C de Romeuf

    LFB, Lille, France

    1 shared publication
  • C. J. Elson

    Department of Pathology and Microbiology, University of Bristol, UK

    1 shared publication
  • D. J. Jackson

    Bristol Institute of Transfusion Sciences, International Blood Group Reference Laboratory, UK

    1 shared publication
  • D. Lee

    From the International Blood Group Reference Laboratory, Bristol, UK; National Blood Service, Manchester, UK; and Bio Products Laboratory, Elstree, UK

    1 shared publication

Latest Publications

  • Comparison of haemoglobin F detection by the acid elution test, flow cytometry and high‐performance liquid chromatography in maternal blood samples analysed for fetomaternal haemorrhage

    by E. Chambers, L. Davies, S. Evans, J. Birchall, B. Kumpel

    Background and Objective: All pregnant women undergoing blood grouping at Southmead Hospital are offered haemoglobinopathy screening by high‐performance liquid chromatography (HPLC). RhD‐negative women who deliver RhD‐positive infants are tested for fetomaternal haemorrhage (FMH) by acid elution (AE). The effectiveness of these two assays for quantitation of FMH was compared with flow cytometry (FC).Materials and Methods: The relationship between expression of haemoglobin F (HbF) in individual cells by AE and FC and quantitation of HbF in haemolysates by HPLC was investigated, using maternal samples with unusually high levels of HbF‐positive maternal cells (F cells) or with large FMH (fetal cells). Standard anti‐D FC was performed to quantitate fetal D‐positive cells in D‐negative women and compared with FMH estimated by AE and HbF FC.Results: AE overestimated FMH when maternal F cells were increased. HbF FC distinguished F cells from fetal cells. Values of HbF determined by HPLC were less than the level of 5% used for investigation of raised fetal haemoglobin, even in the maternal samples with elevated F cells or massive FMH.Conclusions: To quantitate FMH, measurement of HbF using FC was more sensitive and accurate than AE or HPLC. HbF FC is the method of choice when results from routine investigation using AE or standard anti‐D FC are discrepant or when there is maternal and fetal RhD compatibility.


  • Placental immunology and maternal alloimmune responses

    by B. M. Kumpel, M. S. Manoussaka

    During pregnancy, women are tolerant of their semi‐allogeneic fetus whilst not being immunosuppressed and indeed readily form alloantibodies. This ‘Immunological Paradox of Pregnancy’ may be explained by an understanding of placental anatomy and immunology. Trophoblast cells form the interface between the fetus and maternal tissues and blood and escape allorecognition because they lack classical human leucocyte antigen (HLA) class I and II molecules. Local immunoregulation, or tolerance, in the decidua is mediated partly by HLA‐G+ extravillous trophoblasts (EVT) that invade the tissue and prevent killing by maternal natural killer cells, cytotoxic T cells and macrophages. Placental hormones orchestrate the composition and regulatory function of maternal immune cells. In contrast, syncytiotrophoblast cells at the surface of chorionic villi, in contact with maternal blood, maintain a state of mild maternal systemic immunity via activation of innate immunity and skewing towards humoral immunity. This enables maintenance of a healthy immune system in pregnant women and robust protective antibody responses to pathogens whilst enabling survival of the fetus. However, this has the unfortunate consequence that pregnant women readily form alloantibodies to incompatible alloantigens on fetal red cells, platelets and leucocytes if fetomaternal haemorrhage (FMH) occurs. The antibodies are initially low affinity but after re‐immunization with further FMH become functionally effective, high‐titre IgG.


  • Ultrastructural localization of glycoprotein IIIa (GPIIIa, β3 integrin) on placental syncytiotrophoblast microvilli: implications for platelet alloimmunization during pregnancy

    by Belinda M. Kumpel, Karin Sibley, David J. Jackson, Graham White, Peter W. Soothill

    BACKGROUND: Fetal and neonatal alloimmune thrombocytopenia due to anti‐human platelet antigen (HPA)‐1a more commonly occurs in first pregnancies, unlike hemolytic disease of the newborn. Anti‐D is produced after D+ fetomaternal hemorrhage; this usually occurs at parturition. Anti‐HPA‐1a could develop during pregnancy if maternal immunization is stimulated by HPA‐1a expressed not only on platelets but also on other fetal cells.STUDY DESIGN AND METHODS: An ultrastructural study of fetal placental chorionic villi was undertaken to determine the localization of glycoprotein (GP)IIIa carrying the HPA‐1a/1b polymorphism. First trimester and term villi were incubated with a monoclonal antibody (MoAb) to GPIIIa or with positive control MoAbs (anti‐placental alkaline phosphatase and ED822 MoAb) to villous syncytiotrophoblast (ST). Binding of MoAbs was detected with a gold‐conjugated secondary antibody before processing the tissues and examination of ultrathin sections in an electron microscope.RESULTS: Gold particles were evident on microvilli on the apical surface of ST when labeled with anti‐GPIIIa and the placenta‐specific MoAbs but not with an isotype control antibody. Immunolabeling for anti‐GPIIIa on first trimester ST was similar to that of term ST.CONCLUSION: The apical surface of the ST is bathed in maternal blood. During the natural regenerative process of human placenta, senescent parts of the ST are shed into maternal blood during pregnancy. This includes both apoptotic ST nuclei and microparticulate ST debris. The presence of GPIIIa on this circulating ST cellular material could be the source of HPA‐1a alloantigen causing primary immunization of susceptible primigravidae early enough for anti‐HPA‐1a to cause fetal thrombocytopenia during a first pregnancy.


  • Lessons learnt from many years of experience using anti-D in humans for prevention of RhD immunization and haemolytic disease of the fetus and newborn

    by B. M. Kumpel

    Summary: For 40 years prophylactic anti-D has been given to D-negative women after parturition to prevent haemolytic disease of the fetus and newborn. Monoclonal or recombinant anti-D may provide alternatives to the current plasma-derived polyclonal IgG anti-D, although none of them have yet proved as effective in phase 1 clinical trials. The variation in efficacy of the antibodies may have been influenced by heterogeneity in glycosylation of anti-D produced from different cell lines. Some aspects of the conduct of the human studies, most notably the use of low doses of anti-D and target D positive red cells in vivo, may aid the design of the clinical development of other immunomodulatory drugs in order to minimize adverse effects.


  • Phenotype and mRNA Expression of Syncytiotrophoblast Microparticles Isolated from Human Placenta

    by Belinda Kumpel, May‐Jean King, Suren Sooranna, Dave Jackson, Jane Eastlake, Rong Cheng, Mark Johnson

    Fetal and neonatal alloimmune thromboctyopenia due to maternal human platelet antigen (HPA)‐1a antibodies affects primigravidas. Immunization must occur early in pregnancy before fetal platelets enter maternal blood via fetomaternal hemorrhage. The HPA‐1a antigen is located on platelet glycoprotein (GP)IIIa (CD61, β3 integrin), which is also present on the placental syncytiotrophoblast (ST) and in direct contact with maternal blood. Since ST debris is shed into maternal blood during pregnancy, this material might be immunogenic in vivo. For experimental purposes, we prepared and characterized ST microparticles (STMPs) in vitro from term placentas. Phenotype analysis by flow cytometry and Western blotting showed that STMP expressed more placental alkaline phosphatase (PLAP) than GPIIIa. Quantitative real‐time PCR demonstrated expression of human placental lactogen (HPL), human chorionic gonadotrophin (HCG), and GPIIIa by STMP, in the order HPL > HCG > GPIIIa. PLAP, HPL, and HCG are trophoblast‐specific proteins. These STMPs may be a useful model for studying the natural ST debris in plasma of pregnant women.


  • Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti‐D immunoglobulin: more questions than answers

    by B. M. Kumpel

    Prophylactic anti‐D is a very safe and effective therapy for the suppression of D‐immunization and prevention of haemolytic disease of the foetus and newborn. The primary mode of action of anti‐D is rapid clearance of fetal D‐positive red cells from the maternal circulation, mediated by interactions with immunoglobulin G Fc receptors on macrophages in the spleen. Many anti‐D monoclonal antibodies (mAb) have been produced by a variety of methods. Twelve anti‐D mAbs were tested in eight studies for their ability to mediate clearance of autologous red cells, and 13 antibodies studied in seven trials of the clearance of D‐positive red cells injected into D‐negative subjects. Antibodies produced by human B‐cell lines, mouse–human heterohybridomas and Chinese hamster ovary cells varied in their activity with none being quite as effective as polyclonal anti‐D. However, clearance mediated by recombinant anti‐D produced by rat YB2/0 cells was extremely rapid, faster than polyclonal anti‐D, but with haemolysis and some hepatic accumulation of red cells observed in one study. Two human anti‐D mAbs prevented D‐immunization. In contrast, anti‐D mAbs from heterohybridomas increased the incidence and rapidity of anti‐D responses. It is hypothesised that unnatural glycosylation of monoclonal anti‐D produced by some cell lines may have caused these unexpected results. In some antibodies, unusual oligosaccharides on anti‐D may have affected binding to Fc receptors resulting in reduced red cell clearance. For others, non‐human glycoforms of anti‐D might have bound to innate immune recognition molecules promoting pro‐inflammatory reactions. These extensive data on the clinical activity of monoclonal anti‐D produced by cell lines derived from four species will inform the future development of monoclonal anti‐D for RhD prophylaxis.


  • Open Access

    EDITORIAL

    by Belinda M. Kumpel